^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | BNT327 (PD-L1 inhibitor, VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.
Published date:
05/25/2023
Excerpt:
Twenty-six patients with platinum-resistant ovarian cancer had an ORR of 15.4% (4/26), and 27 patients with NSCLC (with EGFR mutations) had an ORR of 18.5% (5/27)….PM8002 showed encouraging antitumor activity and good safety in patients with advanced solid tumors.
DOI:
10.1200/JCO.2023.41.16_suppl.2536
